PDSB - PDS Biotechnology Corporation
NASDAQ
->
Healthcare
->
Biotechnology
Florham Park,
United States
Type: Equity
PDSB price evolution
PDSB
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $56.56 | $54.25 | $60.62 | $65.2 |
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $59.06 | $56.84 | $63.35 | $67.97 |
| Long term investments | ||||
| Property, plant & equipment | $0.34 | $0.35 | $0.4 | $0.48 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $0.34 | $0.35 | $0.4 | $0.48 |
| Total investments | ||||
| Total assets | $59.39 | $57.19 | $63.75 | $68.45 |
| Current liabilities | ||||
| Accounts payable | $6.98 | $5.37 | $4.41 | $2.07 |
| Deferred revenue | ||||
| Short long term debt | $4.22 | $0.05 | $0.11 | $0.2 |
| Total current liabilities | $13.63 | $9.15 | $7.9 | $4.13 |
| Long term debt | $19.63 | $23.55 | $23.41 | $23.31 |
| Total noncurrent liabilities | $19.63 | $23.55 | $23.41 | $23.31 |
| Total debt | $23.85 | $23.6 | $23.52 | $23.51 |
| Total liabilities | $33.26 | $32.7 | $31.31 | $27.44 |
| Shareholders' equity | ||||
| Retained earnings | -$144.5 | -$133.6 | -$122.75 | -$111.22 |
| Other shareholder equity | ||||
| Total shareholder equity | $26.13 | $24.48 | $32.44 | $41.01 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $56.56 | $73.82 | $65.24 | $28.84 |
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $59.06 | $76.48 | $66.84 | $30.34 |
| Long term investments | ||||
| Property, plant & equipment | $0.34 | $0.53 | $0.36 | $0.55 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $0.34 | $0.53 | $0.36 | $0.55 |
| Total investments | ||||
| Total assets | $59.39 | $77.01 | $67.2 | $30.89 |
| Current liabilities | ||||
| Accounts payable | $6.98 | $1.22 | $1.31 | $1.42 |
| Deferred revenue | ||||
| Short long term debt | $4.22 | $0.29 | $0.26 | $0.12 |
| Total current liabilities | $13.63 | $9.82 | $3.76 | $3.27 |
| Long term debt | $19.63 | $23.18 | $0.23 | $0.49 |
| Total noncurrent liabilities | $19.63 | $23.18 | $0.23 | $0.49 |
| Total debt | $23.85 | $23.47 | $0.49 | $0.61 |
| Total liabilities | $33.26 | $33.01 | $3.99 | $3.76 |
| Shareholders' equity | ||||
| Retained earnings | -$144.5 | -$101.56 | -$60.7 | -$43.79 |
| Other shareholder equity | $0 | |||
| Total shareholder equity | $26.13 | $44 | $63.21 | $27.13 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $7.47 | $6.45 | $8 | $5.84 |
| Selling, general & administrative | $2.94 | $4.07 | $4.69 | $3.58 |
| Total operating expenses | $10.41 | $10.52 | $12.7 | $9.42 |
| Operating income | -$10.41 | -$10.52 | -$12.7 | -$9.42 |
| Income from continuing operations | ||||
| EBIT | -$10.41 | -$10.52 | -$12.7 | -$9.42 |
| Income tax expense | $0 | -$1.41 | ||
| Interest expense | $0.49 | $0.33 | $0.24 | $0.24 |
| Net income | ||||
| Net income | -$10.9 | -$10.85 | -$11.53 | -$9.66 |
| Income (for common shares) | -$10.9 | -$10.85 | -$11.53 | -$9.66 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $27.76 | $29.43 | $11.25 | $7.92 |
| Selling, general & administrative | $15.28 | $12.24 | $10.18 | $6.96 |
| Total operating expenses | $43.05 | $41.67 | $21.44 | $14.9 |
| Operating income | -$43.05 | -$41.67 | -$21.44 | -$14.9 |
| Income from continuing operations | ||||
| EBIT | -$43.05 | -$41.67 | -$21.43 | -$14.85 |
| Income tax expense | -$1.41 | -$1.2 | -$4.52 | |
| Interest expense | $1.3 | $0.38 | ||
| Net income | ||||
| Net income | -$42.94 | -$40.85 | -$16.92 | -$14.85 |
| Income (for common shares) | -$42.94 | -$40.85 | -$16.92 | -$14.85 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$10.9 | -$10.85 | -$11.53 | -$9.66 |
| Operating activities | ||||
| Depreciation | -$0.03 | $0.05 | $0.07 | $0.07 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $1.35 | $2.07 | $2.11 | $2.08 |
| Total cash flows from operations | -$8.46 | -$7.18 | -$4.81 | -$13.19 |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | ||||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $10.78 | $0.82 | $0.25 | $4.59 |
| Net borrowings | -$0.01 | -$0.01 | -$0.01 | -$0.02 |
| Total cash flows from financing | $10.77 | $0.8 | $0.24 | $4.57 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $2.31 | -$6.37 | -$4.57 | -$8.62 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$42.94 | -$40.85 | -$16.92 | -$14.85 |
| Operating activities | ||||
| Depreciation | $0.18 | $0.24 | $0.25 | $0.18 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $7.61 | $5.2 | $4.07 | $0.43 |
| Total cash flows from operations | -$33.64 | -$25.71 | -$12.49 | -$13.15 |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | ||||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $16.44 | $10.01 | $48.89 | $29.83 |
| Net borrowings | -$0.06 | $24.55 | ||
| Total cash flows from financing | $16.38 | $34.29 | $48.89 | $29.83 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$17.26 | $8.58 | $36.4 | $16.68 |
News
Fundamentals
| Market cap | $107.56M |
|---|---|
| Enterprise value | $74.85M |
| Shares outstanding | 33.09M |
| Revenue | $0.00 |
|---|---|
| EBITDA | -$42.87M |
| EBIT | -$43.05M |
| Net Income | -$42.94M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -2.50 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | -1.75 |
| EV/EBIT | -1.74 |
| P/S ratio | N/A |
| P/B ratio | 4.12 |
| Book/Share | 0.79 |
| Cash/Share | 1.71 |
| EPS | -$1.30 |
|---|---|
| ROA | -69.04% |
| ROE | -138.45% |
| Debt/Equity | 1.27 |
|---|---|
| Net debt/EBITDA | 0.54 |
| Current ratio | 4.33 |
| Quick ratio | 4.33 |